BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26035122)

  • 41. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
    Miyake T; Honma Y; Urano T; Kato N; Suzumiya J
    Int J Oncol; 2015 Jul; 47(1):315-24. PubMed ID: 25936828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway.
    Liu DL; Bu HQ; Jin HM; Zhao JF; Li Y; Huang H
    Mol Med Rep; 2014 Dec; 10(6):3027-34. PubMed ID: 25242370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
    Zhang GN; Liang Y; Zhou LJ; Chen SP; Chen G; Zhang TP; Kang T; Zhao YP
    Cancer Lett; 2011 Dec; 313(2):137-44. PubMed ID: 22030254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
    Byun S; Shin SH; Lee E; Lee J; Lee SY; Farrand L; Jung SK; Cho YY; Um SJ; Sin HS; Kwon YJ; Zhang C; Tsang BK; Bode AM; Lee HJ; Lee KW; Dong Z
    Carcinogenesis; 2015 Dec; 36(12):1580-9. PubMed ID: 26464195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
    Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
    Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
    Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry.
    Duan Q; Zhao H; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
    Sci Rep; 2017 Oct; 7(1):12891. PubMed ID: 29018223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.
    Hayashi T; Ding Q; Kuwahata T; Maeda K; Miyazaki Y; Matsubara S; Obara T; Natsugoe S; Takao S
    Cancer Sci; 2012 May; 103(5):889-96. PubMed ID: 22320450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
    Kawanami T; Takiguchi S; Ikeda N; Funakoshi A
    Oncol Rep; 2012 Mar; 27(3):867-72. PubMed ID: 22200743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
    Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ
    Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
    Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
    Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
    Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
    Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
    Kumar S; Inigo JR; Kumar R; Chaudhary AK; O'Malley J; Balachandar S; Wang J; Attwood K; Yadav N; Hochwald S; Wang X; Chandra D
    Cancer Lett; 2018 Jan; 413():82-93. PubMed ID: 29107110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.